: biologics interleukin-17 interleukin-23 psoriasis T helper type 17 a b s t r a c t Psoriasis is a chronic inflammatory disease mediated by a complex interplay between immune system and keratinocytes. Initially considered as a keratinocyte proliferation/differentiation disorder, an immune dysregulation was confirmed after the successful treatment of psoriasis with cyclosporine. The yingeyang theory, or T helper type 1 (Th1)/Th2 concept, was then introduced to explain the rarity of atopic dermatitis in patients with psoriasis and the aggravation of psoriasis after interferon-g treatment. However, recent advances have revised the Th1/Th2 paradigm after the discovery of a novel subset of T cells, called Th17 cells. Th17 cells produce interleukin (IL)-17 and IL-22, and have other important downstream proinflammatory effects on skin, leading to clinical and pathological features typical of psoriasis. Nowadays, emerging evidence suggests integrative and complicated inflammatory circuits among Th1 and Th17 cells and keratinocytes in the pathogenesis of psoriasis, with Th17 cells playing a central role. Herein, we review the biology of Th17 cells as well as the reciprocal interplay between Th17 and regulatory T cells in psoriasis. Integration of the IL-23/Th17 axis into a revised concept of psoriasis has already been translated into novel therapeutic strategies. Studies investigating the effect and molecular mechanism of conventional and biological therapy for psoriasis on the IL-23/Th17 pathway were also discussed.
IL-17 was first identified in rodent T-cell hybridoma. 3 Later, IL-23 was shown to mediate the expansion of IL-17-producing cells, and the finding led to the discovery of Th17 cells. 4e6 The concept of potently inhibit the development of murine Th17 cells. 2, 7 Langrish et al 5 showed that proliferation of Th17 cells highly depends on IL-23. Data presented by Dong 8 and Murphy et al 9 indicated that inducible T-cell costimulator and IL-23 were required for IL-17 expression, but not for IFN-g expression, in the mice models of experimental autoimmune encephalomyelitis and collageninduced arthritis. Like Th1 and Th2 cells, Th17 cells produce a group of distinctive cytokines. Th17 cells do not produce IFN-g or IL-4; instead, they produce IL-17 and express the IL-23 receptor (IL-23R). 5, 7 Additionally, chemokine (C-C motif) receptor (CCR)4 and CCR6 are major chemokine receptors involved in Th17 response, which are different from predominant expression of CXCR6, CCR5, and CXCR3 in Th1 cells as well as CCR3, CCR4, and CCR8 in Th2 cells, respectively. 10 Based on the unique priming cytokines, lineagespecific transcriptional regulators, cytokine products, and cytokine receptors, Th17 cells are widely accepted as a separate and early lineage of effector T cells, rather than cells differentiating directly from Th1 or Th2 cells.
Basics of Th17
A sequence homology with IL-17A and is mainly involved in mucosal host defense mechanism. 24 Although the ability of IL-17B, IL-17C, and IL-17D to express proinflammatory cytokines is similar to that of IL-17A and IL-17F, the role of the former in the immune system
has not yet been fully elucidated. 24 IL-17E is not produced by Th17 cells but produced by Th2 cells, cecal patch CD4 þ and CD8 þ T cells, mast cells, and eosinophils. 24 It enhances Th2 cell immune response by inducing IL-4, IL-5, IL-13, IgE production, and eosinophilia, contributing to the host defense against nematodes and allergic disorders. 24 Circumstantial evidence also suggests that Th17 cells regulate the development of autoimmune diseases, such as psoriasis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and asthma. 5, 8, 32 Emerging data also investigate the role of Th17 cells in the etiopathogenesis of periodontal disease. 33 In 1998, Teunissen et al 34 showed detectable levels of IL-17 mRNA in lesional psoriatic skin, but not in nonlesional skin. Subsequent studies also demonstrated increased expression of IL-17A, IL-17C, IL-17F, and IL-23 subunits in lesional psoriatic skin compared with nonlesional and normal skin. 35 Kagami et al 36 demonstrated that circulating Th17, Th22, and Th1 cells were increased in psoriasis patients, and blood levels of Th17 and Th1 cells also decreased after therapy with TNF-a antagonist (infliximab). Intradermal injection of IL-23 in mice led to lesions with histopathological features resembling psoriasis. 37 CD4 þ Th17 cells were present in higher numbers in psoriatic lesions than in healthy skin and decreased after treatment. 38 Zaba et al 39 showed that psoriatic dermal dendritic cells could induce T-cell proliferation, and polarize T cells to become Th17 and Th1 cells. Both IL-17A and IL-22 induce keratinocyte expressing chemokine (C-C motif) ligand 20 (CCL20), which attracts Th17 cells to sites of inflammation via CCL20eCCR6 signaling and drives epidermal acanthosis, linking the IL23/Th17 axis with pathology of psoriasis. 40 42 Collectively, these data have confirmed the central role of IL23/Th17 in the pathogenesis of psoriasis. IL-21 is not only a Th17 cytokine but also a differentiation factor for Th17 cells when present alone or with IL-6 or TGF-b. 18 Loss of IL-21 or its receptor had decreased Th17 cells in mice, which resulted in a large increase in T-regulatory cells (T-reg) in vitro. 18, 20, 43 Additionally, IL-21 as well as TGF-b also acts in an autocrine manner to promote Th17 differentiation. IL-23, a member of IL-12 family, is a heterodimeric cytokine formed by a p40 chain, which is shared with IL-12, and a unique p19 chain. IL-23 is secreted by dendritic cells, macrophages, other antigen-presenting cells as well as keratinocytes, 46 and plays a pivotal role in the survival and proliferation of Th17 cells after priming with TGF-b and IL-6. 5, 9 In IL-23-deficient mice, experimental autoimmune encephalomyelitis resistance correlates with the absence of IL-17-producing T cells. 47 Ortega et al 47 showed that Tc17 cells from psoriasis-inflamed skin tissue produced IL-17, IL-21, and IL-22 (Th17-related cytokines) as well as TNF-a and IFN-g (Th1-related cytokines). Tc17 cells also displayed T-cell receptor/CD3-mediated cytotoxic abilities to kill target cells. 47 Notably, when IL-12 was added to the Tc17 cell culture, the Tbet (Th1-associated transcription factor) was clearly upregulated. 48 Recent studies have suggested that Tc17 cells also play a role in the pathogenesis of psoriasis. Res et al 49 Additionally, further studies showed that Th22 cells were increased in psoriatic lesions 51, 52 and, like Th17 cells, showed an epidermal homing characteristic. 50 Th22-producing IL-22 amplified TNF-a-induced signals, leading to a proinflammatory microenvironment during skin immune reactions. 50 These findings implicated that Th22 may also contribute significantly to the pathogenesis of psoriasis.
Reciprocal relationship between Th17 and T-reg
Contribution of TGF-b to Th17 differentiation was initially viewed with some surprise, as TGF-b induced FOXP3, which was considered as a transcription factor associated with the generation of T-reg. 54 T-reg plays an indispensable role in maintaining immunological unresponsiveness to self-antigens and in suppressing excessive immune responses deleterious to the host. 55 73 Consistent with these findings, several groups showed that treatment with TNF-a antagonists suppressed synergistic TNF-a/IL-17 gene transcripts to a greater extent than TNF-a "single-regulated" gene products.
70,74e
76 Clinical response to TNF-a antagonists was correlated with early reduction of IL-23 and IL-17A, followed by decreased Th1-associated genes later.
69,76
Effect of conventional agents on the IL23/Th17 axis in psoriasis
The successful use of most conventional antipsoriasis treatment was generally based on serendipity, and the exact mode of action was often poorly understood. In this new era of IL23/Th17 in the pathogenesis of psoriasis, the effect of the conventional therapy deserves further investigation. Racz et al 77 16, 19 Subsequently, proinflammatory cytokines such as IL-17A, IL-17F, and IL-22 act on keratinocytes, leading to aberrant differentiation and proliferation and to the production of antimicrobial peptides, chemokines, and angiogenic factors ( Figure 1) . 40, 101, 102 These mediators are also able to recruit and activate immune cells to the lesional skin and set up a positive feedback loop, amplifying the core response. 8, 103 Taken together, Th17cells, cytokines, and activated keratinocytes interact to establish an activated inflammatory network, ultimately leading to the clinical features of psoriasis (Figure 1 ). With the advances in understanding the immunopathogenesis of psoriasis, the treatment of psoriasis has undergone a revolution. Therapeutic strategies targeting the immunopathogenic pathway of Th17 provide patients with therapies showing favorable therapeutic benefits and safety not previously seen in the treatment of psoriasis. 
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